Spirapril

Spirapril

File:Spirapril.svg
Systematic (IUPAC) name
(8S)-7-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
Clinical data
Pregnancy category	D
Routes of administration	Oral
Legal status
Legal status	℞ (Prescription only)
Pharmacokinetic data
Bioavailability	50%
Metabolism	converted to spiraprilat
Biological half-life	30 to 35 hours
Excretion	Hepatic and renal
Identifiers
CAS Number	83647-97-6
ATC code	C09AA11 (WHO)
PubChem	CID 5311447
Chemical data
Formula	C22H30N2O5S2
Molar mass	466.616 g/mol[[]]
(verify)

Spirapril hydrochloride (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension.

Like many ACE inhibitors, this is a prodrug which is converted to the active metabolite spiraprilat following oral administration. Unlike other members of the group, it is eliminated both by renal and hepatic routes which may allow for greater use in patients with renal impairment.

However data on its effect upon the renal function is conflicting.

It is produced synthetically by combining the following two pharmaceutical intermediates:

(s)-1,4 Dithia-7-azaspiro (4,4)-nonane-8-(s)-carboxylic acid hydrobromide CAS 75776-79-3

and

N-[1-(s)-ethoxycarbonyl-3-phenylpropyl)-L-Alanine ( ECPPA) [1]

Footnotes

it:Spirapril